Laboratory medicine in France : A jeopardized situation.
Copyright (c) 1997 Elsevier Science B.V. All rights reserved.
The expenses for health care in France have risen considerably during the present decade, ranking third after USA and Canada in the Western world.
In spite of the very low cost of laboratory medicine (2.4% of the total expenditure in 1995), clinical laboratories have undergone a severe squeeze, due to two limiting factors ; a decrease in the ordering of laboratory tests from private physicians and a reduction in the total expenses for laboratory services from the Social Security.
Consequently, there has been unemployment of technical and secretarial staff and severe restriction in investment for buying new equipment.
However, hospital laboratories will manage to assume their challenge in developing robotics, automation, molecular pathology techniques and expert systems.
Private laboratories, in spite of their efforts to follow the technological advances in automation, will survive thanks to consolidation of regional networks that operate in a cooperative rather than competitive mode.
Therefore, the challenge will be not in the adaptation of clinical laboratories, but in the limitation of overspending at the national level and in modification of the behaviour of irresponsible citizens accustomed to spending freely on health care services.
Mots-clés Pascal : Système santé, Laboratoire, Biologie clinique, France, Europe, Contrôle coût, Dépense, Economie santé, Secteur public, Secteur privé, Marché travail, Personnel laboratoire, Investissement, Equipement biomédical, Sécurité sociale
Mots-clés Pascal anglais : Health system, Laboratory, Clinical biology, France, Europe, Cost control, Expenditure, Health economy, Public sector, Private sector, Labour market, Laboratory staff, Investment, Biomedical equipment
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0107852
Code Inist : 002B30A01B. Création : 22/06/1998.